Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22.

@article{Ray2009PrognosticUO,
  title={Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22.},
  author={Kausik K Ray and Christopher Paul Cannon and Richard Cairns and David A. Morrow and Paul M. Ridker and Eugene Braunwald},
  journal={Arteriosclerosis, thrombosis, and vascular biology},
  year={2009},
  volume={29 3},
  pages={424-30}
}
OBJECTIVES The purpose of this study was to compare the prognostic utility of apoB/AI, total cholesterol/HDL (TC/HDL) ratio, non-HDL cholesterol (non-HDL-C), or hs-CRP as predictors of clinical risk among patients receiving statin therapy after acute coronary syndromes (ACS). METHODS AND RESULTS Patients with ACS were randomized in the PROVE IT-TIMI 22 trial to either pravastatin 40 mg or atorvastatin 80 mg. Cox regression models adjusting for confounders were used to assess the relationship… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 70 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 16 references

Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial

  • DA Morrow, JA de Lemos, +6 authors E. Braunwald
  • 2006

Similar Papers

Loading similar papers…